Literature DB >> 16903943

Complete response of a recurrent advanced urachal carcinoma treated by S-1/cisplatin combination chemotherapy.

Yoshiyuki Kojima1, Yasuyuki Yamada, Hideyuki Kamisawa, Shoichi Sasaki, Yutaro Hayashi, Kenjiro Kohri.   

Abstract

We report a case of recurrent advanced urachal carcinoma with right internal iliac node and left lung metastases in a 34-year-old man. After receiving partial cystectomy including en bloc resection of the urachus and with bilateral pelvic lymph node dissection, he was treated with five courses of S-1 and cisplatin combination chemotherapy. He remains free from the disease after a 30-month follow-up period. S-1/cisplatin combination chemotherapy is suggested to be a potent tool for controlling advanced urachal carcinoma.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16903943     DOI： 10.1111/j.1442-2042.2006.01487.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN： 0919-8172            Impact factor:   3.369


  11 in total

Review 1.  Current Understanding of Urachal Adenocarcinoma and Management Strategy.

Authors:  Mélanie Claps; Marco Stellato; Emma Zattarin; Alessia Mennitto; Pierangela Sepe; Valentina Guadalupi; Roberta Mennitto; Filippo G M de Braud; Elena Verzoni; Giuseppe Procopio
Journal:  Curr Oncol Rep       Date:  2020-01-27       Impact factor: 5.075

2.  A case of metastatic urachal adenocarcinoma treated with several different chemotherapeutic regimens.

Authors:  Christine Elser; Joan Sweet; Sendhil K Cheran; Masoom A Haider; Michael Jewett; Srikala S Sridhar
Journal:  Can Urol Assoc J       Date:  2012-02       Impact factor: 1.862

3.  Clinical outcome of urachal cancer in Japanese patients.

Authors:  Tatsuro Hayashi; Takeshi Yuasa; Sho Uehara; Yasushi Inoue; Shinya Yamamoto; Hitoshi Masuda; Yasuhisa Fujii; Iwao Fukui; Junji Yonese
Journal:  Int J Clin Oncol       Date:  2015-07-03       Impact factor: 3.402

4.  Next-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma.

Authors:  Somak Roy; Dinesh Pradhan; Wayne L Ernst; Stephanie Mercurio; Yana Najjar; Rahul Parikh; Anil V Parwani; Reetesh K Pai; Rajiv Dhir; Marina N Nikiforova
Journal:  Mod Pathol       Date:  2017-05-26       Impact factor: 7.842

5.  National Incidence, Management and Survival of Urachal Carcinoma.

Authors:  Dearbhaile C Collins; Kyra Velázquez-Kennedy; Sandra Deady; Adrian P Brady; Paul Sweeney; Derek G Power
Journal:  Rare Tumors       Date:  2016-10-05

6.  Metastatic Urothelial Carcinoma with Glandular Differentiation That Confirmed the Response by Autopsy Specimen to Second-Line mFOLFOX6 (Fluorouracil, Oxaliplatin, and Leucovorin) plus Bevacizumab Chemotherapy.

Authors:  Taku Naiki; Toshiki Etani; Aya Naiki-Ito; Kana Fujii; Ryosuke Ando; Keitaro Iida; Takashi Nagai; Yosuke Sugiyama; Motoo Nakagawa; Noriyasu Kawai; Takahiro Yasui
Journal:  Case Rep Oncol       Date:  2017-11-27

7.  Long-term survival of a patient with invasive signet-ring cell carcinoma of the urinary bladder managed by combined s-1 and Cisplatin adjuvant chemotherapy.

Authors:  Takashi Hamakawa; Yoshiyuki Kojima; Taku Naiki; Yasue Kubota; Takahiro Yasui; Keiichi Tozawa; Yutaro Hayashi; Kenjiro Kohri
Journal:  Case Rep Urol       Date:  2013-05-08

Review 8.  Surgical and chemotherapeutic experience regarding a urachal carcinoma with repeated relapse: case report and literature review.

Authors:  Liang Zong; Ping Chen
Journal:  World J Surg Oncol       Date:  2013-08-01       Impact factor: 2.754

9.  A Case of Metastatic Urachal Carcinoma Treated With FOLFIRI (irinotecan and 5-Fluorouracil/leucovorin) Plus Bevacizumab.

Authors:  Tomohiro Kanamaru; Taro Iguchi; Nao Yukimatsu; Yasuomi Shimizu; Yuki Kohyama; Hirokazu Tachibana; Minoru Kato; Takeshi Yamasaki; Satoshi Tamada; Tatsuya Nakatani
Journal:  Urol Case Rep       Date:  2014-12-23

Review 10.  Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data.

Authors:  Henning Reis; Ulrich Krafft; Christian Niedworok; Orsolya Módos; Thomas Herold; Mark Behrendt; Hikmat Al-Ahmadie; Boris Hadaschik; Peter Nyirady; Tibor Szarvas
Journal:  Dis Markers       Date:  2018-03-12       Impact factor: 3.434
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.